FDA Approval Insights: Sacituzumab Govitecan in Urothelial Cancer

Jul 22, 09:34 PM

Dr. Tagawa discusses the FDA approval of sacituzumab govitecan in urothelial cancer, key efficacy and safety data from the pivotal TROPHY-U-01 trial, and expectations for the confirmatory TROPiCS-04 trial.